No matches

13 search results for: heterogeneity

Content temporarily unavailable

Confidence Across the Spectrum: Addressing the Heterogeneity of CSU

This infographic explores the heterogeneity of chronic spontaneous urticaria (CSU) across patient subpopulations and highlights differences in demographic and clinical characteristics that may impact disease burden and management.

Content temporarily unavailable

Heterogeneity and Unpredictability: Challenges With the Diagnosis and Evaluation of CSU

In this video from EADV 2025, Dr. Netchiporouk discusses the clinical features, diagnosis, and burden of CSU

Content temporarily unavailable

Broadening the Lens: Clinical and Immunological Insights That Inform CSU Management

Professors Metz, Netchiporouk, and Hawkes discuss the clinical features, pathophysiology, and therapeutic landscape of CSU, at EADV 2025.

Content temporarily unavailable

Broadening the Lens: Clinical and Immunological Insights That Inform CSU Management

Experience this engaging presentation by Professors Martin Metz, Elena Netchiporouk, and Jason Hawkes to explore emerging therapies for chronic spontaneous urticaria.

Content temporarily unavailable

Prurigo Nodularis Management Goals: From Itch Control to Improved Quality of Life

Tune in as Dr. Sarina Elmariah describes the management goals for patients with prurigo nodularis.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: FinlandChange country/region